Here we investigate the therapeutic efficacy of prophylactically administered WIN55,212-2, a mixed cannabinoid (CB1/CB2) agonist, and AM1710, a CB2-preferring agonist, on the development of chemotherapy-induced neuropathy in the paclitaxel model. Here, CNR2 is linked to neuropathy.